Inozyme Pharma Inc logo

INZY

Inozyme Pharma Inc

$3.4

Earnings Summary

Revenue
$0Mn
Net Profits
$-16.88Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Inozyme Pharma Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Inozyme Pharma Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Inozyme Pharma Inc’s net profit fell -52.8% since last year same period to $-16.88Mn in the Q1 2022. On a quarterly growth basis, Inozyme Pharma Inc has generated 9.97% jump in its net profits since last 3-months.

Net Profit Margins:

Inozyme Pharma Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Inozyme Pharma Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Inozyme Pharma Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.48
EPS Estimate Current Year
-0.48

Highlights

EPS Estimate Current Quarter:

Inozyme Pharma Inc’s earning per share (EPS) estimates for the current quarter stand at -0.48 - a 41.46% jump from last quarter’s estimates.

EPS Estimate Current Year:

Inozyme Pharma Inc’s earning per share (EPS) estimates for the current year stand at -0.48.

Key Ratios

Key ratios of the Inozyme Pharma Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.71
Return on Assets (ROA)
-0.29
Return on Equity (ROE)
-0.51
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Inozyme Pharma Inc’s earning per share (EPS) fell -51.06% since last year same period to -0.71 in the Q1 2022. This indicates that the Inozyme Pharma Inc has generated -51.06% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Inozyme Pharma Inc’s return on assets (ROA) stands at -0.29.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Inozyme Pharma Inc’s return on equity (ROE) stands at -0.51.

Dividend Per Share (DPS):

Inozyme Pharma Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
-0.82
-0.71
13.41%

Company Information

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization. Through the company's in-depth understanding of the biological pathways involved in mineralization, company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. Inozyme is initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies.

Organisation
Inozyme Pharma Inc
Employees
38
Industry
Health Technology